This paper demonstrates that pretargeted PET imaging of CNS targets using monoclonal antibodies is feasible, achieving specific binding to Aβ-bound antibodies.

Nuclear Medicine and Biology · Nov 1, 2025Peer-reviewedNeuroscience

Characterization of AZ12464237 as a high affinity, non-nucleotide antagonist radioligand for the P2Y12 receptor

E. Johanna L. Stéen, Efthalia-Natalia Tousiaki, Lee P. Kingston, Berend van der Wildt, Nikolett Lénárt, Wissam Beaino, Mariska Verlaan, Barbara A. Zarzycka, Bastian Zinnhardt, Ádám Dénes, Luca B. Gobbi, Iwan J. P. de Esch, Charles S. Elmore, Albert D. Windhorst, Michael Honer, Rob Leurs

This paper characterizes [3H]AZ12464237 as a high-affinity radioligand for the P2Y12 receptor, showing selectivity and utility in in vitro studies.

Biochemical Pharmacology · Apr 3, 2025Peer-reviewedPharmacology & Toxicology

First in-human PET study of 3 novel tau radiopharmaceuticals: RO6958948

Dean Foster Wong, Robert A. Comley, Hiroto Kuwabara, Paul B. Rosenberg, Susan M. Resnick, Susanne Ostrowitzki, Cristina Vozzi, Frank Boess, Esther S. Oh, Constantine George Lyketsos, Michael Honer, Luca B. Gobbi, Gregory Klein, Noble George, Lorena Gapasin, , Edilio Borroni

This paper reports the first human PET study of three novel tau radiopharmaceuticals, finding that [18F]RO-948 shows superior characteristics for tau pathology characterization in Alzheimer's disease.

Journal of Nuclear Medicine · May 4, 2018Peer-reviewedNeuroscience